Fifth Third Bancorp Buys 2,834 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fifth Third Bancorp lifted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 21.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 16,013 shares of the medical research company's stock after acquiring an additional 2,834 shares during the period. Fifth Third Bancorp's holdings in IQVIA were worth $2,823,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of IQV. American National Bank & Trust bought a new position in IQVIA in the 1st quarter worth about $26,000. ST Germain D J Co. Inc. increased its holdings in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after buying an additional 76 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of IQVIA during the fourth quarter valued at $39,000. Lee Danner & Bass Inc. purchased a new stake in IQVIA during the fourth quarter valued at about $44,000. Finally, Zions Bancorporation N.A. lifted its position in shares of IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after acquiring an additional 85 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of research analyst reports. Citigroup reissued a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Redburn Partners set a $188.00 price target on shares of IQVIA in a report on Friday, May 23rd. Barclays reduced their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research report on Wednesday, May 7th. Finally, Robert W. Baird decreased their target price on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA has a consensus rating of "Moderate Buy" and a consensus target price of $226.32.

IQVIA Trading Up 0.4%

IQV stock traded up $0.60 during trading on Wednesday, hitting $154.70. The company had a trading volume of 675,266 shares, compared to its average volume of 1,622,236. The stock has a market cap of $26.76 billion, a price-to-earnings ratio of 21.06, a PEG ratio of 1.74 and a beta of 1.28. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The firm has a 50-day moving average price of $147.84 and a 200-day moving average price of $176.89. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The firm's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.54 earnings per share. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.